Key result
Ezetimibe shows potential metabolic and liver benefits beyond lipid lowering, but cardiovascular efficacy remains unproven.
Answers are grounded in this paper and cite their sources.
Ezetimibe is a relatively new drug that inhibits the absorption of dietary cholesterol in the small intestine. It is a low density lipoprotein-cholesterol (LDL-C) lowering medication that acts directly on the intestine by inhibiting Niemann-Pick C1 Like1 (NPC1L1). Recently, results of the ARBITER 6-HALTS trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies) and the ENHANCE trial (Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression) showed that ezetimibe had no effect on atherosclerosis despite producing a marked decrease in LDL-C. Recent studies show a potential benefit of ezetimibe in treating insulin resistance, non-alcoholic fatty liver disease (NAFLD), gallstones and dyslipidaemia associated with chronic renal failure and organ transplantation. All of these conditions are known to be associated with an increase in risk of cardiovascular disease (CVD) and further studies are needed to assess the potential benefits of ezetimibe in these therapeutics areas.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2010) conducted a review in Cardiovascular disease, insulin resistance, non-alcoholic fatty liver disease, gallstones, dyslipidaemia. Ezetimibe was evaluated. Ezetimibe shows potential benefits in treating insulin resistance, NAFLD, gallstones, and dyslipidaemia, requiring further studies to assess its impact on reducing cardiovascular disease risk.
Synapse has enriched 10 related papers. Consider them for comparative context: